Biotech | April 08, 2022
CDSCO approves Phase II/III trial of Akston Bio’s Covid vaccine candidate in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Ind-Ra maintains a neutral outlook for healthcare in FY23
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Air purification system achieves Intertek zero ozone certification
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Data to establish the safety profile and human dose of vaccine candidate
Subscribe To Our Newsletter & Stay Updated
